Renalytix announces Medicare issued coverage determination for kidneyintelX.dkd

Renalytix announces that on June 13, 2024 Medicare issued a final Local Coverage Determination, LCD, for the Company’s kidneyintelX.dkd testing. The final LCD can be accessed at LCD – KidneyIntelX and KidneyIntelX.dkd Testing and is effective for dates of service on or after August 1, 2024. The established Medicare price for kidneyintelX.dkd is $950 per test. Distinct CPT Codes have been established for kidneyintelX.dkd and is published in CMS’ 2024 Clinical Lab Fee Schedule. “With final Medicare Coverage, an FDA authorization, and an April recommendation in the international clinical guidelines, kidneyintelX.dkd is poised to be a preventative medicine standard for 14 million people in the United States living with diabetes and kidney disease. We expect this Medicare coverage will prompt additional major coverage decisions and help accelerate testing adoption,” said James McCullough CEO of Renalytix. “We remain focused on incremental sales growth in targeted US regions with a now significantly lower cost of operations.”